Parkinson's Disease With Mild Cognitive Impairment Treated With Nicotinic Agonist Drug

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2022

Primary Completion Date

January 31, 2024

Study Completion Date

April 30, 2024

Conditions
Parkinson DiseaseMild Cognitive Impairment
Interventions
DRUG

AZD0328

Active study drug

DRUG

Placebo

Non-active study drug

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Helse Stavanger HF

OTHER_GOV

collaborator

Michael J. Fox Foundation for Parkinson's Research

OTHER

collaborator

Parkinson's UK

OTHER

collaborator

AstraZeneca

INDUSTRY

collaborator

Masaryk University

OTHER

collaborator

Norges Parkinsonforbund, Norway

UNKNOWN

collaborator

University of Exeter

OTHER

collaborator

Stichting Lygature

UNKNOWN

collaborator

Innovative Medicines Initiative

OTHER

lead

King's College London

OTHER